MorphoSys raises €84m in private placement
This article was originally published in Scrip
Executive Summary
MorphoSys has raised gross proceeds of around €84m in a private placement which will supplement its already healthy cash balance. 2013 has been a real landmark year for the German biotechnology company. Two high profile deals, with Celgene and GlaxoSmithKline, have signaled a coming of age of this formerly pure-play antibody platform enterprise.